Novo Nordisk + OpenAI Push

Novo Nordisk said on April 14 that it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial operations. (biospace.com) The Danish drugmaker said pilot programmes will start across research and development, manufacturing and commercial teams, with full integration planned by the end of 2026. (biospace.com) Novo Nordisk said the tools will be used to analyse large datasets, identify drug candidates and shorten the path from research to patient use. The company also said OpenAI will help train its global workforce in artificial intelligence. (biospace.com) Drug development generates huge volumes of lab, trial and manufacturing data, and companies have been testing artificial intelligence as a way to spot patterns faster than human teams can on their own. Novo Nordisk said this deal is aimed at both research work and the day-to-day systems that make and ship medicines. (cnbc.com) The announcement lands as drugmakers widen their use of OpenAI beyond chat tools and into regulated parts of the business. Sanofi announced an OpenAI collaboration in May 2024, Moderna said in April 2024 that it was deploying ChatGPT Enterprise across the company, and Thermo Fisher announced its own OpenAI tie-up in October 2025. (sanofi.com) (openai.com) (corporate.thermofisher.com) Novo Nordisk had already been building its artificial intelligence stack before this deal. In June 2025, NVIDIA said it was working with Novo Nordisk and the Danish Centre for AI Innovation on custom models and agents tied to Denmark’s Gefion sovereign artificial intelligence supercomputer. (investor.nvidia.com) (novonordiskfonden.dk) Novo Nordisk said the OpenAI partnership includes strict data protection, governance and human oversight, a point that matters in a business where manufacturing records, regulatory submissions and trial data are tightly controlled. (biospace.com) Investors treated the announcement as part of Novo Nordisk’s broader push to speed development and operations. CNBC reported the shares were up 2.8 percent shortly after the opening bell on April 14. (cnbc.com) The next test is execution: Novo Nordisk has set a deadline of late 2026 to move from pilots to companywide use. That gives the company about 20 months to show that artificial intelligence can do more than help discover drugs — it also has to help make and deliver them. (biospace.com)